AGF Management Ltd. Buys New Shares in Vaxcyte, Inc. (NASDAQ:PCVX)

AGF Management Ltd. bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 28,444 shares of the company’s stock, valued at approximately $2,328,000.

A number of other institutional investors have also recently bought and sold shares of PCVX. Whipplewood Advisors LLC purchased a new stake in Vaxcyte in the fourth quarter valued at approximately $28,000. Smartleaf Asset Management LLC grew its holdings in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after purchasing an additional 260 shares during the period. Blue Trust Inc. grew its holdings in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after purchasing an additional 371 shares during the period. Assetmark Inc. grew its holdings in Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after purchasing an additional 775 shares during the period. Finally, Meeder Asset Management Inc. grew its holdings in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on PCVX. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Guggenheim reiterated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $147.50.

Vaxcyte Trading Up 1.8 %

Shares of PCVX stock opened at $74.37 on Friday. The company has a market capitalization of $9.58 billion, a PE ratio of -16.17 and a beta of 1.02. The firm has a fifty day simple moving average of $82.24 and a 200-day simple moving average of $94.26. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. Equities research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Insider Activity

In related news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares of the company’s stock, valued at $11,351,794.37. This represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,250 shares of company stock worth $4,550,258. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.